دورية أكاديمية
أعرض في EDS

Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke.

التفاصيل البيبلوغرافية
العنوان: Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke.
المؤلفون: Correa-Paz C; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Pérez-Mato M; Neuroscience and Cerebrovascular Research Laboratory, Department of Neurology and Stroke Center, La Paz University Hospital, Neuroscience Area of IdiPAZ Health Research Institute, Universidad Autónoma de Madrid, Madrid, Spain., Bellemain-Sagnard M; Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institute Blood and Brain @ Caen-Normandie (BB@C), Caen, France., González-Domínguez M; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Marie P; Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institute Blood and Brain @ Caen-Normandie (BB@C), Caen, France., Pérez-Gayol L; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., López-Arias E; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Del Pozo-Filíu L; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., López-Amoedo S; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Bugallo-Casal A; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Alonso-Alonso ML; Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institute Blood and Brain @ Caen-Normandie (BB@C), Caen, France., Candamo-Lourido M; Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institute Blood and Brain @ Caen-Normandie (BB@C), Caen, France., Santamaría-Cadavid M; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain.; Stroke Unit, Department of Neurology, Hospital Clínico Universitario, A Coruña, Spain., Arias-Rivas S; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain.; Stroke Unit, Department of Neurology, Hospital Clínico Universitario, A Coruña, Spain., Rodríguez-Yañez M; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain.; Stroke Unit, Department of Neurology, Hospital Clínico Universitario, A Coruña, Spain., Iglesias-Rey R; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Castillo J; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Vivien D; Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institute Blood and Brain @ Caen-Normandie (BB@C), Caen, France.; Department of Clinical Research, Caen Normandie University Hospital, Caen, France., Rubio M; Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institute Blood and Brain @ Caen-Normandie (BB@C), Caen, France., Campos F; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain.
المصدر: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism [J Cereb Blood Flow Metab] 2024 Aug; Vol. 44 (8), pp. 1306-1318. Date of Electronic Publication: 2024 Mar 04.
نوع المنشور: Journal Article; Comparative Study
اللغة: English
بيانات الدورية: Publisher: SAGE Publications Country of Publication: United States NLM ID: 8112566 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-7016 (Electronic) Linking ISSN: 0271678X NLM ISO Abbreviation: J Cereb Blood Flow Metab Subsets: MEDLINE
أسماء مطبوعة: Publication: 2016- : Thousand Oaks, CA : SAGE Publications
Original Publication: New York : Raven Press, c1981-
مواضيع طبية MeSH: Tenecteplase*/therapeutic use , Tissue Plasminogen Activator*/therapeutic use , Tissue Plasminogen Activator*/pharmacology , Tissue Plasminogen Activator*/administration & dosage , Fibrinolytic Agents*/therapeutic use , Fibrinolytic Agents*/pharmacology , Fibrinolytic Agents*/administration & dosage, Animals ; Mice ; Humans ; Male ; Stroke/drug therapy ; Disease Models, Animal ; Ischemic Stroke/drug therapy ; Mice, Inbred C57BL
مستخلص: Alteplase (rtPA) remains the standard thrombolytic drug for acute ischemic stroke. However, new rtPA-derived molecules, such as tenecteplase (TNK), with prolonged half-lives following a single bolus administration, have been developed. Although TNK is currently under clinical evaluation, the limited preclinical data highlight the need for additional studies to elucidate its benefits. The toxicities of rtPA and TNK were evaluated in endothelial cells, astrocytes, and neuronal cells. In addition, their in vivo efficacy was independently assessed at two research centers using an ischemic thromboembolic mouse model. Both therapies were tested via early (20 and 30 min) and late administration (4 and 4.5 h) after stroke. rtPA, but not TNK, caused cell death only in neuronal cultures. Mice were less sensitive to thrombolytic therapies than humans, requiring doses 10-fold higher than the established clinical dose. A single bolus dose of 2.5 mg/kg TNK led to an infarct reduction similar to perfusion with 10 mg/kg of rtPA. Early administration of TNK decreased the hemorrhagic transformations compared to that by the early administration of rtPA; however, this result was not obtained following late administration. These two independent preclinical studies support the use of TNK as a promising reperfusion alternative to rtPA.
Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
References: Vasc Health Risk Manag. 2009;5(1):249-56. (PMID: 19436656)
Blood Adv. 2023 Feb 28;7(4):561-574. (PMID: 35482909)
Stroke. 2013 Jan;44(1):255-9. (PMID: 23117722)
Neurology. 2006 Nov 28;67(10):1846-8. (PMID: 17130421)
Lancet Neurol. 2022 Jun;21(6):511-519. (PMID: 35525250)
Cerebrovasc Dis. 2009;28(2):119-23. (PMID: 19506370)
Stroke. 2020 Nov;51(11):3440-3451. (PMID: 33045929)
N Engl J Med. 2008 Sep 25;359(13):1317-29. (PMID: 18815396)
Circulation. 2017 Jan 31;135(5):440-448. (PMID: 27965285)
Stroke. 2017 Dec;48(12):3413-3419. (PMID: 29146878)
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795. (PMID: 36186106)
Stroke. 2019 Mar;50(4):1026–1031. (PMID: 31166683)
Eur Stroke J. 2021 Mar;6(1):I-LXII. (PMID: 33817340)
Stroke. 2016 Dec;47(12):2993-2998. (PMID: 27834743)
Stroke. 2007 Oct;38(10):2771-8. (PMID: 17702959)
J Nanobiotechnology. 2022 Jan 21;20(1):46. (PMID: 35062954)
Stroke Vasc Neurol. 2022 Feb;7(1):1-5. (PMID: 34667106)
J Am Heart Assoc. 2017 Jun 1;6(6):. (PMID: 28572282)
Curr Treat Options Neurol. 2022;24(10):503-513. (PMID: 35965955)
Thromb Haemost. 2010 May;103(5):891-900. (PMID: 20216985)
Lancet Neurol. 2022 Jun;21(6):520-527. (PMID: 35525251)
J Cereb Blood Flow Metab. 2015 Jul;35(7):1206-12. (PMID: 25735920)
J Cereb Blood Flow Metab. 2010 May;30(5):900-3. (PMID: 20216551)
Stroke. 2018 Sep;49(9):2241-2247. (PMID: 30355006)
Stroke Vasc Neurol. 2024 Feb 27;9(1):82-89. (PMID: 37247876)
N Engl J Med. 1993 Sep 2;329(10):673-82. (PMID: 8204123)
Lancet Neurol. 2018 Dec;17(12):1121-1132. (PMID: 30507392)
BMC Neurol. 2019 Aug 2;19(1):181. (PMID: 31375069)
J Thromb Haemost. 2021 Jul;19(7):1618-1628. (PMID: 33834615)
Lancet. 2023 Feb 25;401(10377):645-654. (PMID: 36774935)
Thromb Haemost. 1981 Aug 28;46(2):561-5. (PMID: 6795744)
Stroke. 2015 Jan;46(1):314-20. (PMID: 25395410)
Stroke. 2016 May;47(5):1312-1318. (PMID: 27032444)
J Stroke. 2017 Jan;19(1):50-60. (PMID: 28178410)
Lancet Neurol. 2023 Feb;22(2):117-126. (PMID: 36549308)
J Thromb Thrombolysis. 2021 Feb;51(2):545-551. (PMID: 32936433)
Stroke. 2004 Dec;35(12):2890-5. (PMID: 15514182)
Lancet Neurol. 2015 Apr;14(4):368-76. (PMID: 25726502)
Ann Neurol. 2022 Nov;92(5):860-870. (PMID: 36054449)
Lancet. 2022 Jul 16;400(10347):161-169. (PMID: 35779553)
J Neurol. 2022 Apr;269(4):1913-1920. (PMID: 34415423)
Exp Neurol. 2004 Jan;185(1):154-9. (PMID: 14697326)
Circulation. 1995 Nov 15;92(10):3032-40. (PMID: 7586274)
Transl Stroke Res. 2018 Aug;9(4):347-355. (PMID: 29116527)
فهرسة مساهمة: Keywords: Alteplase; efficacy; preclinical analysis; tenecteplase; thromboembolic model
المشرفين على المادة: WGD229O42W (Tenecteplase)
EC 3.4.21.68 (Tissue Plasminogen Activator)
0 (Fibrinolytic Agents)
تواريخ الأحداث: Date Created: 20240304 Date Completed: 20240814 Latest Revision: 20240825
رمز التحديث: 20240826
مُعرف محوري في PubMed: PMC11342720
DOI: 10.1177/0271678X241237427
PMID: 38436292
قاعدة البيانات: MEDLINE
الوصف
تدمد:1559-7016
DOI:10.1177/0271678X241237427